哌啶-4-羧酸4-氯苄胺 | 885274-77-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 哌啶-4-羧酸4-氯苄胺
• 中文别名: 4-(4-氯苯乙酰胺)哌啶
• 英文名称: Piperidine-4-carboxylic acid 4-chloro-benzylamide
• 英文别名: N-[(4-chlorophenyl)methyl]piperidine-4-carboxamide
• CAS: 885274-77-1
• 化学式: C₁₃H₁₇ClN₂O
• mdl: MFCD04115011
• 分子量: 252.744
• InChiKey: GGXRRCUFJAQOAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	tert-butyl 4-(4-chlorobenzylcarbamoyl)piperidine-1-carboxylate	881833-22-3	C18H25ClN2O3	352.861

反应信息

• 作为反应物：
  描述：

  3-chloro-N-(3-chloropropyl)aniline 、 哌啶-4-羧酸4-氯苄胺 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 反应 48.0h， 生成 1-acetyl-N-(3-(4-(4-chlorobenzylcarbamoyl)piperidin-1-yl)propyl)-N-(3-chlorophenyl)piperidine-4-carboxamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors

  摘要：

  Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.11.013
• 作为产物：
  描述：

  tert-butyl 4-(4-chlorobenzylcarbamoyl)piperidine-1-carboxylate 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 2.0h， 生成 哌啶-4-羧酸4-氯苄胺
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors

  摘要：

  Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.11.013

文献信息

• [EN] LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY<br/>[FR] DÉRIVÉS DE THIOPHÈNE 2,5-DISUBSTITUÉS DE FAIBLE POIDS MOLÉCULAIRE ET LEUR UTILISATION EN THÉRAPIE
  申请人：NOVASAID AB

  公开号：WO2009098282A1

  公开（公告）日：2009-08-13

  A compound of formula (I). The compound is useful for the treatment of disorders such as pain, fever, inflammation and cancer. A method for preparing the compound.

  一种化合物的化学式（I）。该化合物可用于治疗疼痛、发热、炎症和癌症等疾病。一种制备该化合物的方法。
• PIPERIDINE AND PIPERAZINE DERIVATIVES
  申请人：Schiemann Kai

  公开号：US20100222341A1

  公开（公告）日：2010-09-02

  Compounds of the formula (I), in which R 1 , R 2 , R 3 , D, G, Q and W have the meanings indicated in claim ( 1 ), can and be employed for the treatment of tumours.

  式（I）中的化合物，其中R1、R2、R3、D、G、Q和W具有权利要求（1）中指示的含义，可用于治疗肿瘤。
• EP1501467A4
  申请人：——

  公开号：EP1501467A4

  公开（公告）日：2009-08-19
• HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION
  申请人：Bristol-Myers Squibb Company

  公开号：EP1501467A2

  公开（公告）日：2005-02-02
• Piperidin- und Piperazinderivate zur Behandlung von Tumoren
  申请人：Merck Patent GmbH

  公开号：EP2426106B1

  公开（公告）日：2013-07-31